The efficacy of daratumumab both as monotherapy and in combination with standard-of-care regimens in MM has been established in clinical trials (18).The mechanisms of action by which daratumumab exerts its antitumor effects include tumour cell apoptosis upon FcγR cross-linking, CDC, ADCC and ADCP (88). The gene discussed is FCGR2A; the disease is neoplasm.